Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs.
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data. Click for my update on LLY and NVO.
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide),
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
BMJ
49m
Tirzepatide: Obesity injection will get phased rollout to avoid overwhelming GPs
GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...
Yahoo Finance
2h
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
Eli
Lilly
(NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (
tirzepatide
).
Eli
Lilly
...
STAT
2h
Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
1d
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback